diclofenac has been researched along with Adenocarcinoma in 11 studies
Diclofenac: A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt.
diclofenac : A monocarboxylic acid consisting of phenylacetic acid having a (2,6-dichlorophenyl)amino group at the 2-position.
Adenocarcinoma: A malignant epithelial tumor with a glandular organization.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This study aimed to investigate the effect of diclofenac (DCF), a selective COX-2 inhibitor, on cell adhesion molecules and apoptosis in human colon adenocarcinoma cells." | 4.02 | Diclofenac down-regulates COX-2 induced expression of CD44 and ICAM-1 in human HT29 colorectal cancer cells. ( Aslan, M; Çeker, T; Köksoy, S; Yilmaz, Ç, 2021) |
| "Cancer-induced bone pain is described as dull, aching ongoing pain." | 1.42 | Behavioral and neurochemical analysis of ongoing bone cancer pain in rats. ( King, T; Navratilova, E; Okun, A; Porreca, F; Remeniuk, B; Sukhtankar, D; Xie, JY, 2015) |
| "The intraoperative use of NSAIDs in breast cancer patients (Centre 1) is associated with a reduced recurrence rate (HR = 0." | 1.39 | Neutrophil:lymphocyte ratio and intraoperative use of ketorolac or diclofenac are prognostic factors in different cohorts of patients undergoing breast, lung, and kidney cancer surgery. ( Berliere, M; Canon, JL; Coulie, PG; De Kock, M; Forget, P; Kremer, Y; Legrand, C; Machiels, JP; Poncelet, AJ; Stainier, A; Tombal, B, 2013) |
| " The coculture of indomethacin with interleukin-2 (IL-2) augmented LAK cell activity in an indomethacin dose-response manner, and diminished PGE2 content in the corresponding culture supernatant in a reverse dose-response manner." | 1.28 | Prostaglandin E2 from macrophages of murine splenocyte cultures inhibits the generation of lymphokine-activated killer cell activity. ( Chu, TM; Lin, TH; Nakajima, I; Ohnishi, H, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (18.18) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 6 (54.55) | 24.3611 |
| 2020's | 2 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Al-Abdulla, R | 1 |
| Perez-Silva, L | 1 |
| Lozano, E | 1 |
| Macias, RIR | 1 |
| Herraez, E | 1 |
| Abad, M | 1 |
| Segues, N | 1 |
| Bujanda, L | 1 |
| Briz, O | 1 |
| Marin, JJG | 1 |
| Yilmaz, Ç | 1 |
| Köksoy, S | 1 |
| Çeker, T | 1 |
| Aslan, M | 1 |
| Bonaterra, GA | 1 |
| Kelber, O | 1 |
| Weiser, D | 1 |
| Kinscherf, R | 1 |
| Forget, P | 1 |
| Machiels, JP | 1 |
| Coulie, PG | 1 |
| Berliere, M | 1 |
| Poncelet, AJ | 1 |
| Tombal, B | 1 |
| Stainier, A | 1 |
| Legrand, C | 1 |
| Canon, JL | 1 |
| Kremer, Y | 1 |
| De Kock, M | 1 |
| Remeniuk, B | 1 |
| Sukhtankar, D | 1 |
| Okun, A | 1 |
| Navratilova, E | 1 |
| Xie, JY | 1 |
| King, T | 1 |
| Porreca, F | 1 |
| Ilhan, N | 1 |
| Gungor, H | 1 |
| Gul, HF | 1 |
| Eroksuz, H | 1 |
| Sanyal, SN | 1 |
| Kaur, J | 1 |
| Inoue, T | 1 |
| Anai, S | 1 |
| Onishi, S | 1 |
| Miyake, M | 1 |
| Tanaka, N | 1 |
| Hirayama, A | 1 |
| Fujimoto, K | 1 |
| Hirao, Y | 1 |
| Seed, MP | 1 |
| Brown, JR | 1 |
| Freemantle, CN | 1 |
| Papworth, JL | 1 |
| Colville-Nash, PR | 1 |
| Willis, D | 1 |
| Somerville, KW | 1 |
| Asculai, S | 1 |
| Willoughby, DA | 1 |
| Hodgson, DM | 1 |
| Yirmiya, R | 1 |
| Taylor, AN | 1 |
| Ohnishi, H | 1 |
| Lin, TH | 1 |
| Nakajima, I | 1 |
| Chu, TM | 1 |
11 other studies available for diclofenac and Adenocarcinoma
| Article | Year |
|---|---|
Sensitizing gastric adenocarcinoma to chemotherapy by pharmacological manipulation of drug transporters.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; AT | 2020 |
Diclofenac down-regulates COX-2 induced expression of CD44 and ICAM-1 in human HT29 colorectal cancer cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Cell Survival; Colonic Neoplasms; Cyclooxygenase 2 | 2021 |
Mechanisms of the anti-proliferative and anti-inflammatory effects of the herbal fixed combination STW 5 (Iberogast®) on colon adenocarcinoma (HT29) cells in vitro.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; bcl-2-Associated X Prot | 2013 |
Neutrophil:lymphocyte ratio and intraoperative use of ketorolac or diclofenac are prognostic factors in different cohorts of patients undergoing breast, lung, and kidney cancer surgery.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Breast Neoplasms; Carcinoma, Non-Small-Cell | 2013 |
Behavioral and neurochemical analysis of ongoing bone cancer pain in rats.
Topics: Adenocarcinoma; Analgesics, Opioid; Anesthetics, Local; Animals; Anti-Inflammatory Agents, Non-Stero | 2015 |
Expression of Endoglin and Vascular Endothelial Growth Factor as Prognostic Markers in Experimental Colorectal Cancer.
Topics: Adenocarcinoma; Animals; Biomarkers, Tumor; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 2 Inhibi | 2016 |
Induction of apoptosis as a potential chemopreventive effect of dual cycloxygenase inhibitor, diclofenac, in early colon carcinogenesis.
Topics: Adenocarcinoma; Animals; Apoptosis; Biomarkers, Tumor; Blotting, Western; Chemoprevention; Colon; Co | 2010 |
Inhibition of COX-2 expression by topical diclofenac enhanced radiation sensitivity via enhancement of TRAIL in human prostate adenocarcinoma xenograft model.
Topics: Adenocarcinoma; Administration, Topical; Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; C | 2013 |
The inhibition of colon-26 adenocarcinoma development and angiogenesis by topical diclofenac in 2.5% hyaluronan.
Topics: Adenocarcinoma; Administration, Topical; Animals; Apoptosis; Cell Survival; Colonic Neoplasms; Cyclo | 1997 |
Intracerebroventricular interleukin-1beta impairs clearance of tumor cells from the lungs: role of brain prostaglandins.
Topics: Adenocarcinoma; Animals; Brain; Cyclooxygenase Inhibitors; Diclofenac; Ibuprofen; Injections, Intrav | 2001 |
Prostaglandin E2 from macrophages of murine splenocyte cultures inhibits the generation of lymphokine-activated killer cell activity.
Topics: Adenocarcinoma; Animals; Cells, Cultured; Diclofenac; Dinoprostone; Down-Regulation; Female; Immune | 1991 |